Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINAPPS-1: Immunotherapy Feasibility in Antibody-Associated Psychosis
NCT02449746Completed
- Sponsor
- University of Cambridge
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of intravenous immunoglobulin G in psychosis and schizophrenia (2 arms), sponsored by University of Cambridge. Primary endpoint: Percentage of patients who start on allocated care pathway within 2 weeks of randomisation. Started Aug 2015; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
psychosisschizophrenia
Beyond the preview
Go deeper on NCT02449746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449746.